青岛海泰新光科技股份有限公司 第四届董事会第四会议文件 青岛海泰新光科技股份有限公司 2024 年度独立董事述职报告(黄杰刚) 我作为青岛海泰新光科技股份有限公司（以下简称"公司"）的独立董事, 2024 年度我严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 海证券交易所科创板股票上市规则》《青岛海泰新光科技股份有限公司章程》(以 下简称"《公司章程》")等相关法律、法规、规章的规定和要求,诚实、勤勉、 独立地履行职责,积极出席相关会议,认真审议董事会各项议案,切实维护公司 和全体股东尤其是中小股东的合法权益,促进公司规范运作,充分发挥了独立董 事及各专门委员会的作用。 现将 2024 年度履行独立董事职责的情况报告如下: 第四届董事会第四会议文件 (一)出席会议情况 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 黄杰刚,男,1971年生,中国国籍,无境外永久居留权,中国注册会计师、 税务师。毕业于安徽财贸学院会计学专业,本科学历。2009年9月至今,担任 青岛乾泽会计师事务所所长、青岛乾合税务师事务所所长;2014年7月至今, 担任青岛晟融民间资本管理有限公司总经理;201 ...

青岛海泰新光科技股份有限公司 2024 年度独立董事述职报告（宋又强） 青岛海泰新光科技股份有限公司 第四届董事会第四会议文件 作为公司独立董事，我本人及我的直系亲属、主要社会关系均不在公司或其 附属企业任职，不直接或间接持有公司股份，不在直接或间接持有公司已发行股 份 5%或以上或公司前五名股东单位任职，不在公司控股股东、实际控制人的附 属企业任职，没有与公司及其控股股东、实际控制人或其附属企业有重大业务往 1 我作为青岛海泰新光科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 海证券交易所科创板股票上市规则》《青岛海泰新光科技股份有限公司章程》（以 下简称"《公司章程》"）等相关法律、法规、规章的规定和要求，诚实、勤勉、 独立地履行职责，积极出席相关会议，认真审议董事会各项议案，切实维护公司 和全体股东尤其是中小股东的合法权益，促进公司规范运作，充分发挥了独立董 事及各专门委员会的作用。 青岛海泰新光科技股份有限公司 第四届董事会第四会议文件 现将 2024 年度履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）个 ...

现将 2024 年度履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 青岛海泰新光科技股份有限公司 第四届董事会第四次会议文件 青岛海泰新光科技股份有限公司 2024 年度独立董事述职报告（张自力） 我作为青岛海泰新光科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 海证券交易所科创板股票上市规则》《青岛海泰新光科技股份有限公司章程》（以 下简称"《公司章程》"）等相关法律、法规、规章的规定和要求，诚实、勤勉、 独立地履行职责，积极出席相关会议，认真审议董事会各项议案，切实维护公司 和全体股东尤其是中小股东的合法权益，促进公司规范运作，充分发挥了独立董 事及各专门委员会的作用。 张自力（ZILI ZHANG），男，美国国籍,材料科学和工程博士。2012 年 4 月 至 2013 年 4 月，担任 Demand Energy Networks Vice President；2013 年 5 月 至今，担任 Virtuous Intelligent InfoEnergy Owner/Co ...

青岛海泰新光科技股份有限公司 第四届董事会第四会议文件 青岛海泰新光科技股份有限公司 2024 年度独立董事述职报告（李勇） 我作为青岛海泰新光科技股份有限公司（以下简称"公司"）的独立董事， 2024 年度我严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 海证券交易所科创板股票上市规则》《青岛海泰新光科技股份有限公司章程》（以 下简称"《公司章程》"）等相关法律、法规、规章的规定和要求，诚实、勤勉、 独立地履行职责，积极出席相关会议，认真审议董事会各项议案，切实维护公司 和全体股东尤其是中小股东的合法权益，促进公司规范运作，充分发挥了独立董 事及各专门委员会的作用。 现将 2024 年度履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 李勇，男，1989 年出生，中国国籍，硕士研究生学历。2014 年 9 月至 2017 年 3 月担任北京市通商律师事务所律师助理、律师；2017 年 4 月至 2021 年 4 月， 担任北京观韬中茂律师事务所专职律师、合伙人；2021 年 5 月至今，担任北京 德恒律师事务所专职律师、合伙人。目前兼任第十二届 ...

青岛海泰新光科技股份有限公司 第四届董事会第四次会议文件 青岛海泰新光科技股份有限公司 2024 年度独立董事述职报告 (崔军) 我作为青岛海泰新光科技股份有限公司(以下简称"公司")的独立董事, 2024 年度我严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上 海证券交易所科创板股票上市规则》《青岛海泰新光科技股份有限公司章程》(以 下简称"《公司章程》")等相关法律、法规、规章的规定和要求,诚实、勤勉、 独立地履行职责,积极出席相关会议,认真审议董事会各项议案,切实维护公司 和全体股东尤其是中小股东的合法权益,促进公司规范运作,充分发挥了独立董 事及各专门委员会的作用。 现将 2024年度履行独立董事职责的情况报告如下: 一、独立董事的基本情况 第四届董事会第四次会议文件 (一) 出席会议情况 1、董事会、股东大会 2024 年度公司共计召开 9 次董事会会议,即第三届董事会第十八次会议至 第三届董事会第二十四次会议、第四届董事会第一次会议至第四届董事会第二次 会议,2024年度公司共计召开 4 次股东大会,即 2023年年度股东大会、2024 年第一次临时股东大会、2024年第二次临时股东大 ...

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 6609万股，累计占流通股比： 54.8%，较上期变化： 99.51万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.1200 | 1.2000 | -6.67 | 1.5000 | | 每股净资产（元） | 10.81 | 10.63 | 1.69 | 14.02 | | 每股公积金(元) | 4.88 | 5.39 | -9.46 | 7.95 | | 每股未分配利润(元) | 4.78 | 4.26 | 12.21 | 5.15 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 4.43 | 4.71 | -5.94 | 4.77 | | 净利润(亿元) | 1.35 | 1.46 | -7.53 | 1.83 | | 净资产收益率(%) | 10.45 | 11.60 | -9. ...

重要内容提示： 证券代码：688677 证券简称：海泰新光 公告编号：2025-023 青岛海泰新光科技股份有限公司 关于使用部分暂时闲置自有资金及募集资金 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 青岛海泰新光科技股份有限公司（以下简称"公司"或"海泰新光"）于 2025 年 4 月 24 日召开第四届董事会第四次会议、第四届监事会第四次会议， 审议通过了《关于使用部分暂时闲置自有资金及募集资金进行现金管理的议案》， 同意公司在确保不影响募集资金投资项目实施、募集资金安全及日常生产经营 的情况下，使用额度不超过人民币 3 亿元（含 3 亿元）的自有资金及额度不超 过人民币 2 亿元（含 2 亿元）的部分暂时闲置募集资金进行现金管理，用于购 买安全性高、满足保本要求、流动性好的理财产品，上述额度自公司董事会审 议通过之日起 12 个月内有效，在前述额度和期限范围内，资金可循环滚动使用。 公司董事会授权董事长在授权额度和期限内行使现金管理投资决策权并签署相 关合同文件。上述事项在董事会审批权限范围内，无 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-025 青岛海泰新光科技股份有限公司 关于续聘 2025 年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：安永华明会计师事务所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 安永华明会计师事务所（特殊普通合伙）以下简称"安永华明"，于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合作的有限责任制事务 所转制为特殊普通合伙制事务所。安永华明总部设在北京，注册地址为北京市 东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 截至 2024 年年末，安永华明拥有合伙人 251 人，首席合伙人为毛鞍宁先生。 安永华明一直以来注重人才培养，截至 2024 年末拥有执业注册会计师逾 1700 人，其中拥有证券相关业务服务经验的执业注册会计师超过 1500 人,注册会计 师中签署过证券服务业务审计报告的注册会计师逾 500 人。 安永华 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 146,890,114.27, representing a 24.86% increase compared to CNY 117,641,916.58 in the same period last year[3]. - Net profit attributable to shareholders was CNY 46,688,665.42, up 21.45% from CNY 38,442,677.55 year-on-year[3]. - Operating profit for Q1 2025 was ¥53,400,464.56, compared to ¥43,669,497.35 in Q1 2024, reflecting a growth of 22%[12]. - Net profit for Q1 2025 was ¥45,790,558.36, up 21% from ¥37,975,036.47 in Q1 2024[13]. - The company incurred a total operating cost of ¥90,011,178.73 in Q1 2025, an increase from ¥71,244,373.98 in Q1 2024[12]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.39, up from ¥0.32 in Q1 2024[13]. Cash Flow and Investments - The net cash flow from operating activities increased by 61.66%, reaching CNY 63,977,722.34, compared to CNY 39,574,829.10 in the previous year[3]. - Cash flow from operating activities for Q1 2025 was ¥63,977,722.34, significantly higher than ¥39,574,829.10 in Q1 2024[14]. - The company reported a net cash increase of ¥36,416,191.40 in Q1 2025, contrasting with a decrease of ¥159,765,162.08 in Q1 2024[15]. - The company's R&D investment totaled CNY 15,588,599.79, a 4.30% increase from CNY 14,945,675.14 in the same period last year[3]. - Research and development expenses increased to ¥15,588,599.79 in Q1 2025, up from ¥14,945,675.14 in Q1 2024[12]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,547,640,272.85, reflecting a 6.00% increase from CNY 1,460,092,283.49 at the end of the previous year[4]. - The total current assets as of March 31, 2025, amounted to CNY 936,929,623.74, an increase from CNY 851,290,383.20 as of December 31, 2024, representing an increase of approximately 10.1%[10]. - Cash and cash equivalents increased to CNY 560,229,844.98 from CNY 523,890,835.86, reflecting a growth of about 6.9%[11]. - The total liabilities increased to CNY 202,815,067.96 from CNY 154,641,332.66, which is an increase of about 31%[11]. - The company's retained earnings rose to CNY 623,756,903.06 from CNY 577,068,237.64, showing an increase of approximately 8.1%[11]. - The inventory level as of March 31, 2025, was CNY 196,729,965.24, compared to CNY 186,514,537.63 at the end of 2024, marking an increase of about 5.8%[11]. - The company's non-current assets totaled CNY 610,710,649.11, slightly up from CNY 608,801,900.29, reflecting a marginal increase of about 0.3%[11]. - The total equity remained stable at CNY 1,344,825,204.89, with no significant changes reported in the capital structure[11]. Market and Growth Outlook - The company is actively expanding its domestic market, particularly in medical optical products, contributing to revenue growth[7]. - The company anticipates further growth in overseas business revenue as customer demand increases[7]. - The gross profit margin remained stable, with net profit growth being lower than revenue growth due to a decrease in recognized investment income[7]. - The number of ordinary shareholders at the end of the reporting period was 4,446[8]. - The company reported no significant changes in the shareholder structure or participation in margin financing activities during the reporting period[10].

Financial Performance - The company's operating revenue for 2024 was CNY 442,830,242.88, a decrease of 5.90% compared to CNY 470,597,324.29 in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 135,348,545.12, down 7.11% from CNY 145,712,648.46 in 2023[23]. - The net cash flow from operating activities decreased by 28.96% to CNY 112,322,742.56 in 2024, compared to CNY 158,117,742.52 in 2023[23]. - The basic earnings per share for 2024 was CNY 1.12, a decrease of 6.67% from CNY 1.20 in 2023[24]. - The company achieved operating revenue of 442.83 million yuan, a decrease of 5.90% compared to the previous year[140]. - Net profit attributable to shareholders was 135.35 million yuan, a decline of 7.11% year-on-year[140]. Dividend and Share Buyback - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares, totaling approximately 71,422,200 RMB (including tax) based on the remaining shares after buyback[5]. - The total amount for cash dividends and share buybacks is 119,072,568.21 RMB, which represents 87.97% of the net profit attributable to shareholders for the year[5]. - The amount for share buybacks and cancellations is 55,859,256.24 RMB, with the combined total for cash dividends and buybacks reaching 127,281,456.24 RMB, accounting for 94.04% of the net profit attributable to shareholders[5]. - The board of directors has approved the profit distribution plan, which is subject to the approval of the 2024 annual general meeting[6]. Audit and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[4]. - The company has not encountered any significant risks that could materially affect its operations during the reporting period[3]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[11]. - The company has not experienced any issues with a majority of directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[8]. Research and Development - The R&D expenditure as a percentage of operating revenue was 12.23% in 2024, down from 14.00% in 2023[24]. - The company has increased its investment in R&D, market promotion, and overseas subsidiaries, leading to a noticeable rise in related expenses compared to 2023[25]. - The company has applied for 42 new patents and received 32 new authorizations during the reporting period, including 12 new invention patents, accounting for 37.50% of the newly authorized patents[112]. - The total R&D investment for the year was approximately ¥54.15 million, a decrease of 17.83% compared to the previous year, with R&D expenses accounting for 12.23% of total revenue[115]. - The company is focusing on enhancing its marketing network and brand influence to drive sales growth in the domestic market[56]. Market and Sales - The company has established production lines in the US and Thailand to mitigate risks from US tariffs, with nearly 60% of sales coming from US clients[138]. - The company plans to enhance its domestic market presence and brand influence, with significant growth expected in the fourth quarter as customer inventory levels decrease[144]. - The domestic endoscope market is rapidly expanding due to the establishment of a hierarchical diagnosis and treatment system and advancements in minimally invasive surgery[58]. - The company is focusing on optimizing its supply chain and enhancing risk prevention capabilities in response to international trade uncertainties[136]. Product Development and Innovation - The company’s new 4K camera system successfully entered mass production in 2024, achieving rapid growth in the domestic market[37]. - The company has developed a non-contact palm vein recognition technology with a recognition rate of 99.99% and a false recognition rate of only 0.00001%, addressing security concerns in traditional biometric systems[66]. - The company has developed a 3D fluorescence imaging system based on dual CMOS technology, which supports high-speed data transmission and 3D image processing[78]. - The company is developing new products such as 3D endoscope systems and 3D laparoscopes to address clinical challenges and enhance competitiveness in minimally invasive surgery[189]. Financial Position - The company's cash and cash equivalents at the end of the period were CNY 523,890,835.86, which is 35.88% of total assets, down 11.55% from the previous period[166]. - Inventory increased by 9.18% to CNY 186,514,537.63, representing 12.77% of total assets[166]. - The company’s long-term equity investments rose by 293.29% to CNY 53,523,671.16, primarily due to increased investment in a related company[166]. - The company reported a significant increase in accounts receivable by 41.97% to CNY 119,332,508.50, attributed to increased shipments in the fourth quarter[166]. Strategic Partnerships and Collaborations - The company has established a long-term partnership with the international medical device giant, Medtronic, contributing to the development and mass production of core optical components for endoscope systems since 2008[63]. - The company is collaborating with key clients like Danaher Group to meet supply chain reconstruction needs, aiming for new business opportunities[196].